Chronic interstitial nephritis Medical Services in China

Chronic interstitial nephritis (CIN) is a progressive, immune-mediated or toxic-inflammatory disorder characterized by persistent inflammation and fibrosis of the renal interstitium—the supportive tissue surrounding the tubules—leading to gradual loss of kidney function. Unlike acute interstitial nephritis, which often presents with abrupt onset and reversible injury, CIN evolves insidiously over months to years, frequently remaining asymptomatic until significant renal impairment (e.g., reduced GFR, elevated serum creatinine) or structural damage (e.g., tubular atrophy, interstitial fibrosis on biopsy) becomes evident. Pathogenesis involves dysregulated T-cell–mediated immune responses, chronic exposure to nephrotoxic agents (e.g., NSAIDs, proton pump inhibitors, aristolochic acid in herbal remedies), autoimmune conditions (e.g., Sjögren’s syndrome, sarcoidosis), or recurrent infections. Genetic susceptibility (e.g., HLA variants) and epigenetic modifications may amplify inflammatory signaling pathways such as NF-κB and TGF-β, driving fibroblast activation and extracellular matrix deposition. Epidemiologically, CIN accounts for approximately 10–15% of all cases of chronic kidney disease (CKD) requiring renal biopsy in tertiary nephrology centers; its true prevalence is likely underestimated due to underdiagnosis—many patients are labeled broadly as having 'CKD of unknown origin.' Incidence rises with age, peaking in adults aged 50–70 years, and shows modest male predominance (M:F ≈ 1.3:1). Key risk factors include long-term NSAID or PPI use (>6 months), traditional herbal medicine ingestion (especially in East Asia), uncontrolled autoimmune disease, chronic urinary obstruction, and recurrent pyelonephritis. Importantly, environmental exposures—such as occupational solvents or heavy metals—and metabolic comorbidities (e.g., hyperuricemia, diabetes) synergistically accelerate interstitial damage. Quality of life is profoundly impacted: fatigue, nocturia, and cognitive fog commonly precede overt renal failure; as disease advances, patients experience progressive anemia, fluid retention, electrolyte imbalances, and increased cardiovascular morbidity. Psychological burden—including anxiety about dialysis dependency and employment limitations—is high, particularly among working-age adults. Early diagnosis via kidney biopsy remains the gold standard, though non-invasive biomarkers (e.g., urinary β2-microglobulin, NGAL, KIM-1) and advanced MRI techniques (e.g., diffusion-weighted imaging) are emerging to support timely intervention. Without targeted management, CIN progresses to end-stage kidney disease (ESKD) in ~25–40% of cases within 5–10 years, necessitating renal replacement therapy.

Chronic interstitial nephritis (CIN) is a progressive, heterogeneous tubulointerstitial disorder characterized by chronic inflammation and fibrosis of the renal interstitium, leading to gradual loss of kidney function. Unlike acute interstitial nephritis (AIN), which often presents with abrupt onset and reversible injury, CIN evolves insidiously over months to years and frequently culminates in irreversible chronic kidney disease (CKD) and end-stage renal disease (ESRD). The pathogenesis involves persistent immune-mediated injury, dysregulated repair mechanisms, and maladaptive fibrogenesis, resulting in tubular atrophy, interstitial edema, inflammatory cell infiltration (predominantly T lymphocytes and macrophages), and eventual collagen deposition.

Common causes of CIN include prolonged or recurrent exposure to nephrotoxic agents. Drug-induced injury is the most frequent identifiable etiology: long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), particularly in elderly or volume-depleted individuals, induces chronic tubulointerstitial damage via cyclooxygenase inhibition, reduced renal perfusion, and direct tubular toxicity. Analgesic nephropathy—historically linked to phenacetin-containing compound analgesics but now associated with chronic high-dose acetaminophen or NSAID combinations—remains a significant cause, especially in regions with unregulated over-the-counter analgesic access. Other implicated medications include proton pump inhibitors (PPIs), which may trigger subclinical interstitial inflammation that progresses silently; lithium, causing chronic tubulointerstitial fibrosis and nephrogenic diabetes insipidus; and certain antiviral agents (e.g., tenofovir disoproxil fumarate), particularly in patients with preexisting mitochondrial vulnerability or concomitant nephrotoxic exposures.

Autoimmune and systemic disorders constitute another major category. Sjögren syndrome, systemic lupus erythematosus (SLE), sarcoidosis, and IgG4-related disease frequently involve granulomatous or lymphoplasmacytic interstitial infiltration that, if untreated or inadequately controlled, leads to chronic scarring. Inherited metabolic conditions—including primary hyperoxaluria, cystinosis, and Dent disease—cause intratubular crystal deposition or lysosomal dysfunction, resulting in recurrent tubular injury and secondary interstitial fibrosis. Obstructive uropathy (e.g., from chronic stone disease, neurogenic bladder, or untreated ureteral strictures) induces sustained pressure-mediated tubular ischemia and inflammatory cytokine release (e.g., TGF-β, CTGF), accelerating interstitial remodeling.

Triggers of progression include recurrent episodes of acute interstitial nephritis (e.g., repeated NSAID rechallenge), uncontrolled hypertension, persistent proteinuria (>1 g/day), and superimposed acute kidney injury (AKI) on a background of subclinical interstitial disease. Infections—particularly chronic pyelonephritis due to recurrent urinary tract infections in anatomical abnormalities or vesicoureteral reflux—can initiate and perpetuate interstitial inflammation.

Risk factors encompass demographic and clinical variables: advanced age (>65 years), female sex (especially for autoimmune-associated CIN), preexisting CKD (eGFR <60 mL/min/1.73m²), diabetes mellitus (via microvascular injury and enhanced fibrotic signaling), and cardiovascular comorbidities. Chronic hypovolemia (e.g., from diuretic overuse or heart failure) potentiates NSAID- and ACE inhibitor–induced interstitial injury. Socioeconomic factors—including limited healthcare access, delayed diagnosis, and prolonged self-medication with nephrotoxic agents—contribute significantly to disease burden in low-resource settings.

Genetic factors play a modulatory role. Polymorphisms in genes regulating immune response (e.g., HLA-DRB1*04:05 in PPI-induced AIN/CIN), drug metabolism (CYP2C9 variants affecting NSAID clearance), and fibrosis (TGFB1 promoter polymorphisms) influence susceptibility and progression rate. Monogenic disorders such as autosomal dominant tubulointerstitial kidney disease (ADTKD), caused by mutations in UMOD (uromodulin), MUC1, REN, or HNF1B, present with early-onset bland urinary sediment, hyperuricemia, gout, and slow GFR decline—often misdiagnosed as idiopathic CKD. These mutations impair tubular protein folding, trafficking, or transcriptional regulation, initiating endoplasmic reticulum stress and chronic interstitial inflammation.

Environmental factors include endemic exposure to aristolochic acid (found in Aristolochia species used in traditional herbal remedies), which causes aristolochic acid nephropathy—a severe form of CIN with high risk of urothelial malignancy. Heavy metal exposure (e.g., cadmium in contaminated rice or industrial settings, lead in old plumbing or occupational settings) induces proximal tubular mitochondrial dysfunction and oxidative stress. Chronic exposure to silica dust or organic solvents (e.g., trichloroethylene) has also been epidemiologically associated with increased interstitial fibrosis risk, likely through macrophage activation and profibrotic cytokine cascades. Finally, dietary factors—including excessive sodium intake (promoting intrarenal RAAS activation) and chronic low-grade metabolic acidosis from Western diets low in fruits/vegetables—may exacerbate interstitial remodeling via NF-κB and Wnt/β-catenin pathway activation.

Chronic interstitial nephritis (CIN) is a progressive, heterogeneous tubulointerstitial disorder characterized by chronic inflammation and fibrosis of the renal interstitium, with relative sparing of glomeruli in early stages. It accounts for approximately 10–15% of cases of chronic kidney disease (CKD) requiring renal biopsy and may result from diverse etiologies—including drug-induced injury (e.g., NSAIDs, proton pump inhibitors, lithium, tenofovir), autoimmune conditions (e.g., Sjögren syndrome, systemic lupus erythematosus, sarcoidosis), metabolic disorders (e.g., hyperuricemia, hypokalemia), infections (e.g., chronic pyelonephritis, tuberculosis), or idiopathic causes. Unlike acute interstitial nephritis, CIN evolves insidiously over months to years, often presenting with nonspecific or subtle manifestations that delay diagnosis until significant renal parenchymal damage has occurred.

Early symptoms are frequently absent or minimal. Patients may report mild, non-localized fatigue, intermittent low-grade fever (particularly in autoimmune or granulomatous forms), or vague malaise. Subtle changes in urinary habits—such as mild nocturia or decreased urine concentration capacity—may be noted but are rarely attributed to renal pathology. Importantly, early CIN typically preserves glomerular filtration rate (GFR); thus, serum creatinine remains normal or only marginally elevated, and proteinuria is usually absent or trace (<300 mg/day). Urinalysis may reveal sterile pyuria (white blood cells without bacterial growth on culture), mild eosinophiluria (especially in drug-related cases), or occasional renal tubular epithelial cells—findings easily overlooked without high clinical suspicion.

Typical symptoms emerge as interstitial fibrosis advances and tubular dysfunction becomes pronounced. Progressive decline in GFR leads to classic signs of CKD: persistent fatigue, reduced exercise tolerance, anorexia, and unintentional weight loss. Polyuria and polydipsia reflect impaired urinary concentrating ability due to medullary interstitial damage and disrupted countercurrent exchange. Patients often develop non-nephrotic range proteinuria (typically <1 g/day, predominantly low-molecular-weight proteins such as β2-microglobulin and retinol-binding protein), reflecting proximal tubular dysfunction rather than glomerular leak. Hypokalemia or hyperkalemia may occur depending on the dominant tubular defect—distal tubular acidification impairment commonly results in distal renal tubular acidosis (dRTA), manifesting as hyperchloremic metabolic acidosis, hypocitraturia, and nephrocalcinosis. In contrast, proximal RTA (Fanconi-like syndrome) may present with glycosuria, phosphaturia, aminoaciduria, and bicarbonaturia, particularly in heavy metal toxicity or mitochondrial disorders. Hypomagnesemia and normochromic normocytic anemia (due to reduced erythropoietin production and chronic inflammation) are also common.

Accompanying symptoms vary by underlying etiology. In autoimmune-associated CIN (e.g., IgG4-related disease), patients may exhibit lacrimal/salivary gland enlargement, retroperitoneal fibrosis, or autoimmune pancreatitis. Sarcoidosis-related CIN may coexist with bilateral hilar lymphadenopathy, uveitis, or skin lesions. Drug-induced CIN may be associated with cutaneous eruptions (e.g., PPIs), arthralgias, or interstitial lung disease (e.g., NSAID hypersensitivity). Lithium-induced CIN often presents with polyuria refractory to fluid restriction and may precede overt CKD by years. Chronic hyperuricemic nephropathy may be accompanied by tophi, gouty arthritis, or uric acid nephrolithiasis.

Complications arise from both progressive renal failure and specific tubulointerstitial pathophysiology. End-stage kidney disease (ESKD) necessitating dialysis or transplantation is the most severe outcome. Electrolyte and acid-base disturbances—including chronic metabolic acidosis (contributing to bone demineralization and muscle catabolism), hyperkalemia (risking arrhythmias), and calcium-phosphate dysregulation (promoting vascular calcification)—are frequent. Tubulointerstitial fibrosis predisposes to recurrent urinary tract infections due to impaired urinary flow and antimicrobial peptide secretion. Nephrogenic diabetes insipidus increases risk of dehydration and prerenal azotemia. Anemia of chronic disease and renal osteodystrophy further diminish quality of life. Notably, CIN carries higher cardiovascular morbidity than glomerular diseases of equivalent eGFR, likely due to chronic inflammation, endothelial dysfunction, and accelerated vascular calcification.

Diagnosis relies on integration of clinical history, laboratory testing, imaging, and histopathology. Serum creatinine and estimated GFR track longitudinal decline; however, creatinine-based estimates underestimate true GFR in early CIN due to preserved muscle mass and tubular creatinine secretion. Urinalysis should assess for sterile pyuria, eosinophils (using Hansel or Wright stain), and fractional excretion of sodium (FeNa) and potassium (FeK), which are typically normal or low despite rising creatinine—distinguishing it from acute tubular necrosis. Urine protein electrophoresis helps identify tubular vs. glomerular proteinuria. Serum electrolytes, arterial blood gas, and urinary citrate/acid-base parameters aid in diagnosing RTA subtypes. Imaging—particularly non-contrast CT—may show small, contracted kidneys with corticomedullary blurring, while MRI with diffusion-weighted imaging can detect early interstitial edema/fibrosis. Renal biopsy remains the gold standard: histology reveals lymphoplasmacytic infiltrates, tubular atrophy, interstitial fibrosis, and occasionally granulomas or plasma cell aggregates (e.g., IgG4+). Immunofluorescence is typically negative; electron microscopy shows no immune deposits.

Differential diagnosis includes other causes of CKD with predominant tubulointerstitial involvement. Acute interstitial nephritis must be distinguished by temporal association with offending agents, abrupt onset of AKI, and prominent inflammatory infiltrates on biopsy—though chronicity may follow unresolved acute episodes. Autosomal dominant tubulointerstitial kidney disease (ADTKD), formerly MCKD, presents with bland urinalysis, progressive CKD, and family history; genetic testing confirms mutations in UMOD, REN, MUC1, or HNF1B. Analgesic nephropathy (now rare) features papillary necrosis and characteristic radiographic 'ring shadows' on IVU. Multiple myeloma–associated kidney injury shows monoclonal gammopathy, cast nephropathy on biopsy, and absence of interstitial inflammation. Obstructive uropathy may mimic CIN clinically but demonstrates hydronephrosis on ultrasound or CT. Finally, diabetic nephropathy and hypertensive nephrosclerosis typically feature more prominent glomerulosclerosis and less interstitial inflammation—though overlap exists in advanced disease. Accurate differentiation hinges on meticulous history (medication exposure, family history, systemic symptoms), targeted serologic testing (ANA, SSA/SSB, ACE, IgG4, serum free light chains), and timely renal biopsy when etiology remains uncertain.

Chronic interstitial nephritis (CIN) is a progressive, heterogeneous tubulointerstitial disorder characterized by persistent inflammation and fibrosis of the renal interstitium, leading to gradual loss of kidney function. Unlike glomerular diseases, CIN primarily affects the tubules and surrounding interstitium, often sparing the glomeruli until late stages. Etiologies include prolonged exposure to nephrotoxic agents (e.g., NSAIDs, proton pump inhibitors, aristolochic acid), autoimmune conditions (e.g., Sjögren’s syndrome, sarcoidosis, systemic lupus erythematosus), chronic infections (e.g., tuberculosis, pyelonephritis), metabolic disorders (e.g., hyperuricemia, hypercalcemia), and idiopathic causes. Diagnosis relies on clinical history, urinalysis (sterile pyuria, mild proteinuria <1 g/day, tubular dysfunction markers such as low-molecular-weight proteinuria or fractional excretion of sodium abnormalities), serum creatinine trends, imaging (often nonspecific but may show reduced kidney size or increased echogenicity), and—when indicated—renal biopsy demonstrating lymphoplasmacytic infiltration, tubular atrophy, and interstitial fibrosis without significant glomerular involvement.

Conservative management forms the cornerstone of CIN therapy and must be initiated promptly upon diagnosis. First and foremost, strict avoidance of all identifiable nephrotoxins is mandatory: NSAIDs, lithium, certain antibiotics (e.g., vancomycin in high-dose/long-term regimens), and herbal preparations containing aristolochic acid must be discontinued immediately. Patients with hyperuricemia require aggressive uric acid control via dietary modification (low-purine diet, hydration >2 L/day) and pharmacotherapy (allopurinol or febuxostat); similarly, hypercalcemia should be corrected through volume repletion, bisphosphonates if appropriate, and parathyroid hormone evaluation. Blood pressure must be tightly controlled to <130/80 mmHg using renin-angiotensin-aldosterone system (RAAS) inhibitors—preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs)—which confer dual antihypertensive and antifibrotic benefits by reducing intraglomerular pressure and suppressing TGF-β–mediated fibrogenesis. Dietary counseling includes moderate protein restriction (0.6–0.8 g/kg/day of high-biological-value protein), sodium limitation (<2 g/day), and potassium/phosphate monitoring in advanced disease. Regular surveillance of eGFR, electrolytes, urinary biomarkers (e.g., N-acetyl-β-D-glucosaminidase, kidney injury molecule-1), and blood pressure is essential for timely intervention.

Pharmacologic treatment is etiology-specific and largely supportive. In autoimmune-associated CIN (e.g., tubulointerstitial nephritis and uveitis [TINU] syndrome or IgG4-related disease), corticosteroids remain first-line: prednisone 0.5–1 mg/kg/day for 4–6 weeks followed by slow taper over 3–6 months. For steroid-refractory or relapsing cases, immunosuppressants such as mycophenolate mofetil (target dose 1–1.5 g twice daily), azathioprine (2–2.5 mg/kg/day), or rituximab (375 mg/m² weekly × 4 or 1000 mg × 2 doses two weeks apart) may be employed. In sarcoidosis-related CIN, corticosteroids are also primary; methotrexate or TNF-α inhibitors (e.g., infliximab) are considered in refractory granulomatous inflammation. For drug-induced CIN, steroids are generally not recommended unless biopsy confirms severe active inflammation with rapid functional decline—evidence supporting their use remains limited and controversial. Adjunctive therapies under investigation include bardoxolone methyl (Nrf2 activator, though withdrawn from Phase III due to cardiovascular safety signals) and pirfenidone (antifibrotic agent showing promise in preclinical models). Importantly, no FDA- or EMA-approved disease-modifying drugs exist specifically for CIN; thus, pharmacotherapy remains individualized and evidence-informed rather than guideline-mandated.

Surgical intervention has no routine role in CIN management. However, in select scenarios, procedures may be indicated: ureteral stenting or percutaneous nephrostomy is performed for obstructive uropathy contributing to interstitial injury; nephrectomy may be considered in unilateral, severely damaged kidneys causing intractable hypertension or recurrent infection—though this is exceedingly rare. Renal transplantation is the definitive treatment for end-stage kidney disease (ESKD) secondary to CIN. Graft survival rates are comparable to other non-immune-mediated ESKD etiologies, provided the underlying cause (e.g., uncontrolled sarcoidosis or ongoing toxin exposure) is rigorously excluded pre-transplant. Post-transplant recurrence of CIN is uncommon but reported in IgG4-related disease and Sjögren’s syndrome; therefore, close rheumatologic follow-up and maintenance immunosuppression are critical.

China offers distinct advantages in the multidisciplinary management of CIN. First, the national Chronic Kidney Disease (CKD) Prevention and Control Program enables early detection through community-based screening (serum creatinine, urine dipstick, ACR) integrated into primary care, facilitating timely referral to nephrology centers. Second, China’s robust traditional Chinese medicine (TCM) infrastructure complements Western approaches: evidence-based TCM formulas such as Huangkui capsule (Abelmoschus manihot extract) have demonstrated antiproteinuric and anti-inflammatory effects in randomized trials involving tubulointerstitial injury, while acupuncture protocols targeting kidney meridians show adjunctive benefit in symptom control (e.g., fatigue, nocturia). Third, China leads globally in real-world data generation via large-scale electronic health record systems (e.g., the China Kidney Disease Network), enabling rapid identification of epidemiologic patterns—such as the high prevalence of aristolochic acid nephropathy in southern provinces—and informing region-specific prevention strategies. Finally, cost-effective access to generic immunosuppressants and biosimilar biologics significantly improves long-term adherence, particularly among rural and elderly populations.

Recovery and long-term prognosis depend heavily on early diagnosis, etiologic control, and sustained adherence to conservative measures. Patients should undergo quarterly nephrology visits with eGFR trend analysis, annual renal ultrasound, and periodic assessment of tubular function (e.g., urine β2-microglobulin, serum bicarbonate). Lifestyle modifications are non-negotiable: smoking cessation (smoking accelerates interstitial fibrosis), strict glycemic control in diabetic patients (HbA1c <7%), and avoidance of contrast media unless absolutely necessary (with pre-hydration and iso-osmolar agents). Psychological support is integral—chronic kidney disease correlates strongly with depression and anxiety—thus integrating mental health professionals into nephrology care teams is increasingly standard in tier-3 hospitals. Patient education empowers self-monitoring: home blood pressure logs, symptom diaries (e.g., edema, dyspnea), and medication reconciliation tools reduce hospitalizations. With optimal management, many patients stabilize eGFR decline to <2 mL/min/year, preserving native kidney function for decades. Ultimately, CIN demands a proactive, personalized, and perpetually vigilant approach—where prevention, precision, and patient partnership converge to mitigate irreversible fibrosis and preserve quality of life.